ERYP - Erytech Pharma more than doubles after eryaspase fast track designation

Erytech Pharma (NASDAQ:ERYP) +134% post-market - after soaring more than 250% higher earlier - after saying the U.S. Food and Drug Administration granted Fast Track designation to the company's eryaspase for treatment of acute lymphocytic leukemia. The company says the Fast Track designation demonstrates the need for new treatment options for patients who developed hypersensitivity reactions to pegylated asparaginase, which has been part of acute lymphocytic leukemia treatment for several years but is associated with treatment-limiting hypersensitivity in up to 30% of patients. In April 2020, eryaspase was granted Fast Track designation for the development of a second-line treatment of patients with metastatic pancreatic cancer.

For further details see:

Erytech Pharma more than doubles after eryaspase fast track designation